| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 1 | Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i | US13302195 | 2011-11-22 | US09200061B2 | 2015-12-01 | Michael Tesar; Ute Jaeger |
| The present invention provides methods for using recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for CD38, which plays an integral role in various disorders or conditions. These methods take advantage of newly discovered antibodies and surprising properties of such antibodies, such as the ability to bind CD38 of minipig origin and the ability to induce, by cross-linking, specific killing of cells that express CD38. These antibodies as well as the methods for using those antibodies can be used to treat, for example, hematological malignancies such as multiple myeloma. | ||||||
| 2 | CD38 modulated chemotaxis | US11058924 | 2005-02-15 | US20060019308A1 | 2006-01-26 | Frances Lund; Troy Randall; Santiago Partida-Sanchez |
| The present invention relates to methods for modulating the migratory activity of cells expressing CD38 for the treatment of disorders including, but not limited to, inflammation, ischemia, asthma, autoimmune disease, diabetes, arthritis, allergies, infection with pathogenic organisms, such as parasites, and transplant rejection. Such cells include, for example, neutrophils, lymphocytes, eosinophils, macrophages and dentritic cells. The invention further relates to drug screening assays designed to identify compounds that modulate the ADP-ribosyl cyclase activity of CD38 and the use of such compounds in the treatment of disorders involving CD38 modulated cell migration. Additionally, the invention relates to the isolation and characterization of a CD38 homologue from the parasitic flatworm, Schistosoma mansoni. | ||||||
| 3 | Methods for identifying compounds that inhibit CD38 activity | US09982616 | 2001-10-17 | US06955884B2 | 2005-10-18 | Frances E. Lund; Troy D. Randall; Santiago Partida-Sánchez |
| The present invention relates to methods for modulating the migratory activity of cells expressing CD38 for the treatment of disorders including, but not limited to, inflammation, ischemia, asthma, autoimmune disease, diabetes, arthritis, allergies, infection with pathogenic organisms and transplant rejection. Such cells include, for example, neutrophils, lymphocytes, eosinophils, macrophages and dentritic cells. The invention further relates to drug screening assays designed to identify compounds that modulate the ADP-ribosyl cyclase activity of CD38 and the use of such compounds in the treatment of disorders involving CD38 modulated cell migration. The invention is based on the discovery that CD38 ADP-ribosyl cyclase activity is required for chemotaxis. Furthermore, the invention relates to methods for identifying compounds that modulate the enzyme activity of the S. mansoni CD38 homologue and using those compounds in the treatment of pathologic disorders caused by helminth infection. This is based on the discovery that helminths such as S. mansoni express CD38 homologues. | ||||||
| 4 | GENERATION AND PROFILING OF FULLY HUMAN HUCAL GOLD®-DERIVED THERAPEUTIC ANTIBODIES SPECIFIC FOR HUMAN CD38 | US13302195 | 2011-11-22 | US20120076782A1 | 2012-03-29 | Michael Tesar; Stefan Steidl; Robert Friesen |
| The present invention provides novel methods for using recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for CD38, which plays an integral role in various disorders or conditions. These methods take advantage of newly discovered antibodies and surprising properties of such antibodies, such as the ability to bind CD38 of minipig origin and the ability to induce, by cross-linking, specific killing of cells that express CD38. These antibodies as well as the novel methods for using those antibodies can be used to treat, for example, hematological malignancies such as multiple myeloma. | ||||||
| 5 | CD38 modulated chemotaxis | US12703062 | 2010-02-09 | US08084035B2 | 2011-12-27 | Frances E. Lund; Troy D. Randall; Santiago Partida-Sanchez |
| The present invention relates to methods for modulating the migratory activity of cells expressing CD38 for the treatment of disorders including, but not limited to, inflammation, ischemia, asthma, autoimmune disease, diabetes, arthritis, allergies, infection with pathogenic organisms, such as parasites, and transplant rejection. Such cells include, for example, neutrophils, lymphocytes, eosinophils, macrophages and dentritic cells. The invention further relates to drug screening assays designed to identify compounds that modulate the ADP-ribosyl cyclase activity of CD38 and the use of such. compounds in the treatment of disorders involving CD38 modulated cell migration. Additionally, the invention relates to the isolation and characterization of a CD38 homologue from the parasitic flatworm, Schistosoma mansoni. | ||||||
| 6 | CD38 MODULATED CHEMOTAXIS | US12703062 | 2010-02-09 | US20100297148A1 | 2010-11-25 | Frances E. Lund; Troy D. Randall; Santiago Partida-Sanchez |
| The present invention relates to methods for modulating the migratory activity of cells expressing CD38 for the treatment of disorders including, but not limited to, inflammation, ischemia, asthma, autoimmune disease, diabetes, arthritis, allergies, infection with pathogenic organisms, such as parasites, and transplant rejection. Such cells include, for example, neutrophils, lymphocytes, eosinophils, macrophages and dentritic cells. The invention further relates to drug screening assays designed to identify compounds that modulate the ADP-ribosyl cyclase activity of CD38 and the use of such. compounds in the treatment of disorders involving CD38 modulated cell migration. Additionally, the invention relates to the isolation and characterization of a CD38 homologue from the parasitic flatworm, Schistosoma mansoni. | ||||||
| 7 | CD38 modulated chemotaxis | US09982616 | 2001-10-17 | US20020127646A1 | 2002-09-12 | Frances E. Lund; Troy D. Randall; Santiago Partida-Sanchez |
| The present invention relates to methods for modulating the migratory activity of cells expressing CD38 for the treatment of disorders including, but not limited to, inflammation, ischemia, asthma, autoimmune disease, diabetes, arthritis, allergies, infection with pathogenic organisms and transplant rejection. Such cells include, for example, neutrophils, lymphocytes, eosinophils, macrophages and dentritic cells. The invention further relates to drug screening assays designed to identify compounds that modulate the ADP-ribosyl cyclase activity of CD38 and the use of such compounds in the treatment of disorders involving CD38 modulated cell migration. The invention is based on the discovery that CD38 ADP-ribosyl cyclase activity is required for chemotaxis. Furthermore, the invention relates to methods for identifying compounds that modulate the enzyme activity of the S. mansoni CD38 homologue and using those compounds in the treatment of pathologic disorders caused by helminth infection. This is based on the discovery that helminths such as S. mansoni express CD38 homologues. | ||||||
| 8 | COMPOSITION FOR PREVENTING OR TREATING DIABETES COMPRISING NAD GLYCOHYDROLASE INHIBITOR AS ACTIVE INGREDIENT | US13656039 | 2012-10-19 | US20130123142A1 | 2013-05-16 | Uh-Hyun Kim; Tae-Sik Nam; Kwang-Hyun Park; Byung-Ju Kim |
| The present invention provides a composition for preventing or treating diabetes, comprising an NAD glycohydrolase (NADase) inhibitor as an active ingredient. The NAD glycohydrolase (NADase) inhibitor according to the present invention has the effect of reducing blood glucose levels and promoting insulin secretion and thus can be effectively used as a therapeutic agent for diabetes, particularly type II diabetes. | ||||||
| 9 | Mutant forms of meningococcal ADP-ribosylating toxin | US10526125 | 2003-09-01 | US07858096B2 | 2010-12-28 | Mariagrazia Pizza; Vega Masignani |
| NMB1343 is an ADP-ribosylating toxin from Neisseria meningitidis. The invention provides a mutant toxin having a substitution at one or more of amino Glu-109, Glu-111 or Glu-120. The mutations(s) is/are preferably Glu to Asp. The protein of the invention preferably has reduced or eliminated ADP-ribosyltransferase and/or NAD-glycohydrolase activity relative to the wild-type protein. | ||||||
| 10 | SM38 nucleic acid molecules | US11058924 | 2005-02-15 | US07695933B2 | 2010-04-13 | Frances E. Lund; Troy D. Randall; Santiago Partida-Sanchez |
| The present invention relates to methods for modulating the migratory activity of cells expressing CD38 for the treatment of disorders including, but not limited to, inflammation, ischemia, asthma, autoimmune disease, diabetes, arthritis, allergies, infection with pathogenic organisms, such as parasites, and transplant rejection. Such cells include, for example, neutrophils, lymphocytes, eosinophils, macrophages and dentritic cells. The invention further relates to drug screening assays designed to identify compounds that modulate the ADP-ribosyl cyclase activity of CD38 and the use of such compounds in the treatment of disorders involving CD38 modulated cell migration. Additionally, the invention relates to the isolation and characterization of a CD38 homologue from the parasitic flatworm, Schistosoma mansoni. | ||||||
| 11 | Mutant forms of meningococcal adp-ribosylating toxin | US10526125 | 2003-09-01 | US20060269563A1 | 2006-11-30 | Mariagrazia Pizza; Vega Masignani |
| NMB1343 is an ADP-ribosylating toxin from Neisseria meningitidis. The invention provides a mutant-toxin having a substitution at one or more of amino Glu-109, Glu-111 or Glu-120. The mutations(s) is/are preferably Glu to Asp. The protein of the invention preferably has reduced or eliminated ADP-ribosyltransferase and/or NAD-glycohydrolase activity relative to the wild-type protein. | ||||||
| 12 | Cd38 modulated chemotaxis | JP2007180160 | 2007-07-09 | JP2007319162A | 2007-12-13 | LUND FRANCES E; RANDALL TROY D; PARTIDA-SANCHEZ SANTIAGO |
| <P>PROBLEM TO BE SOLVED: To provide a method for identifying a compound for modulating CD38 enzyme activities, and a method for modulating the migratory activity of cells expressing the CD38. <P>SOLUTION: The drug screening assay designed to identify a compound that modulates the ADP-ribosyl cyclase activity of the CD38 and the use of such compounds in the treatment of disorders involving CD38 modulated cell migration are provided. <P>COPYRIGHT: (C)2008,JPO&INPIT | ||||||
| 13 | CD38 MODULATED CHEMOTAXIS | EP01981689 | 2001-10-17 | EP1326998A4 | 2005-05-11 | LUND FRANCES E; RANDALL TROY D; PARTIDA-SANCHEZ SANTIAGO |
| 14 | MUTANT FORMS OF MENINGOCOCCAL ADP-RIBOSYLATING TOXIN | EP03748401.1 | 2003-09-01 | EP1534836B1 | 2006-12-13 | PIZZA, Mariagrazia; MASIGNANI, Vega |
| NMB1343 is an ADP-ribosylating toxin from Neisseria meningitidis. The invention provides a mutant toxin having a substitution at one or more of amino Glu-109, Glu-111 or Glu-120. The mutations(s) is/are preferably Glu to Asp. The protein of the invention preferably has reduced or eliminated ADP-ribosyltransferase and/or NAD-glycohydrolase activity relative to the wild-type protein. | ||||||
| 15 | Chemotaxis, which is regulated by Cd38 | JP2002535531 | 2001-10-17 | JP4139214B2 | 2008-08-27 | パーティダ−サンシェズ，サンティアゴ; ランド，フランセス，イー．; ランドール，トロイ，ディー． |
| 16 | Chemotaxis, which is regulated by Cd38 | JP2002535531 | 2001-10-17 | JP2004518414A | 2004-06-24 | パーティダ−サンシェズ，サンティアゴ; ランド，フランセス，イー．; ランドール，トロイ，ディー． |
| 本発明は、炎症、虚血、喘息、自己免疫疾患、糖尿病、関節炎、アレルギー、病原性生物による感染、及び移植拒絶反応を含む（ただしこれらに限定されない）障害を治療するための、ＣＤ３８を発現する細胞の遊走活性を調節する方法に関する。 このような細胞としては、例えば好中球、リンパ球、好酸球、マクロファージ、及び樹状細胞が挙げられる。 本発明はさらに、ＣＤ３８のＡＤＰ−リボシルシクラーゼ活性を調節する化合物を同定するよう設計された薬物スクリーニングアッセイ、ならびにＣＤ３８により調節される細胞遊走が関係する障害の治療におけるこのような化合物の使用に関する。 本発明は、ＣＤ３８のＡＤＰ−リボシルシクラーゼ活性が走化性にとって必要であるという発見に基づく。 さらに、本発明は、マンソン住血吸虫ＣＤ３８相同体の酵素活性を調節する化合物を同定する方法、ならびに蠕虫感染により引き起こされる病原性障害の治療におけるこれらの化合物の使用に関する。 これは、マンソン住血吸虫等の蠕虫がＣＤ３８相同体を発現する、という発見に基づく。 | ||||||
| 17 | Composition for preventing or treating diabetes comprising nad glycohydrolase inhibitor as active ingredient | EP12189201.2 | 2012-10-19 | EP2584041A1 | 2013-04-24 | Kim, Uh-Hyun; Nam, Tae-Sik; Park, Kwang-Hyun; Kim, Byung-Ju |
The present invention provides a composition for preventing or treating diabetes, comprising an NAD glycohydrolase (NADase) inhibitor as an active ingredient. The NAD glycohydrolase (NADase) inhibitor according to the present invention has the effect of reducing blood glucose levels and promoting insulin secretion and thus can be effectively used as a therapeutic agent for diabetes, particularly type II diabetes. |
||||||
| 18 | MUTANT FORMS OF MENINGOCOCCAL ADP-RIBOSYLATING TOXIN | EP03748401.1 | 2003-09-01 | EP1534836A1 | 2005-06-01 | PIZZA, Mariagrazia; MASIGNANI, Vega |
| NMB1343 is an ADP-ribosylating toxin from Neisseria meningitidis. The invention provides a mutant toxin having a substitution at one or more of amino Glu-109, Glu-111 or Glu-120. The mutations(s) is/are preferably Glu to Asp. The protein of the invention preferably has reduced or eliminated ADP-ribosyltransferase and/or NAD-glycohydrolase activity relative to the wild-type protein. | ||||||
| 19 | CD38 MODULATED CHEMOTAXIS | EP01981689.1 | 2001-10-17 | EP1326998A2 | 2003-07-16 | LUND, Frances E.; RANDALL, Troy D.; PARTIDA-SANCHEZ, Santiago |
| The present invention relates to methods for modulating the migratory activity of cells expressing CD38 for the treatment of disorders including, but not limited to, inflammation, ischemia, asthma, autoimmune disease, diabetes, arthritis, allergies, infection with pathogenic organisms and transplant rejection. Such cells include, for example, neutrophils, lymphocytes, eosinophils, macrophages and dentritic cells. The invention further relates to drug screening assays designed to identify compounds that modulate the ADP-ribosyl cyclase activity of CD38 and the use of such compounds in the treatment of disorders involving CD38 modulated cell migration. The invention is based on the discovery that CD38 ADP-ribosyl cyclase activity is required for chemotaxis. Furthermore, the invention relates to methods for identifying compounds that modulate the enzyme activity of the S. mansoni CD38 homologue and using those compounds in the treatment of pathologic disorders caused by helminth infection. This is based on the discovery that helminths such as S. mansoni express CD38 homologues. | ||||||
| 20 | 엔에이디 글리코하이드롤라제 억제제를 유효성분으로 포함하는 당뇨병의 예방 또는 치료용 조성물 | KR1020120116718 | 2012-10-19 | KR1020130044183A | 2013-05-02 | 김우현; 남태식; 박광현; 김병주 |
| PURPOSE: A composition for prevention and treatment of diabetes including a NAD glycohydrolase inhibitor as an active ingredient is provided to be used as a cure for diabetes, especially type 2 diabetes, by accelerating hypoglycemic and insulin secretion. CONSTITUTION: A composition for prevention and treatment of diabetes comprises a development inhibitor or an activity inhibitor of NADase as an active ingredient. A NADase is originated from a mammal. The NADase is encoded as a base sequence of sequence number 1 or 2. Diabetes is type 2 diabetes. The active inhibitor is any one selected from a group comprised of antisense nucleotide, siRNA(short interfering RNA), and shRNA(short hairpin RNA) for complementarily uniting to mRNA of a NADase gene. | ||||||
QQ群二维码
意见反馈
意见反馈